1. Opening Hook

Imagine waiting for your food delivery, only to get a message: “Delayed, but don’t worry, you’ll still get it next week.” That’s basically Hikal’s Q1 — shipments worth ₹50 cr deferred, Pharma EBIT loss, and FDA gifting them an OAI (Official Action Indicated) tag at their Bangalore site. Crop protection stayed flat (yay, stable boredom), while management assured investors that “Q4 will be the strongest.” Shareholders, meanwhile, are practicing yoga for patience.

2. At a Glance

• Revenue – ₹380 cr (↓7% YoY): Pharma deferments stole the show.
• EBITDA – ₹25 cr (↓56% YoY): Margins collapsed to 6.5% vs 14.3% LY.
• PAT – Loss-making zone: EBIT loss in Pharma, crop just flat.
• Pharma Biz – ₹203 cr (↓12%): OAI → customers cautious → deferments.
• Crop Biz – ₹178 cr (flat YoY): Oversupply & China still bullying prices.
• Debt-Equity – 0.54: Balance sheet okay, patience balance low.

3. Management’s Key Commentary

“Deferment of shipments in Pharma hit Q1.”
(Translation: Customers ghosted us till FDA drama clears.)

“OAI status was procedural, not data integrity.”
(Translation: We messed up forms, not formulas.)

“No orders cancelled, just deferred.”
(Translation: ₹50 cr parked in Q2/Q3 like a fixed deposit.)

“Crop protection revenue flat; overcapacity persists.”
(Translation: Everyone’s warehouses are more stuffed than Big Bazaar in Diwali sale.)

“CDMO pipeline remains healthy.”
(Translation: Our WhatsApp with global clients still buzzing, cash flow not yet.)

“Q4 will be strongest quarter.”
(Translation: Please don’t dump our stock before New Year.)

4. Numbers Decoded

5. Analyst Q&A

• Deferment quantum? Mgmt: ₹50 cr pushed to Q2/Q3, not lost.
  (Translation: Don’t panic, your thali is late, not cancelled.)
• OAI status impact? Mgmt: Procedural only, CAPA 75–80% done, full by Sept.